American Society of Hirudotherapy

Vestibular Migraine (Investigational Adjunct)

Investigational adjunct for refractory vestibular migraine; migraine prophylaxis (propranolol, topiramate, amitriptyline) and vestibular rehabilitation remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for vestibular migraine. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for vestibular migraine is investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for vestibular migraine was identified in our literature search. Treatments used for vestibular migraine (per Barany Society criteria), mostly extrapolated from migraine care, with very limited placebo-controlled evidence specific to vestibular migraine: acute migraine-specific medications (triptans, ditans, gepants), preventive therapy (beta-blockers propranolol/metoprolol, topiramate, amitriptyline, CGRP monoclonal antibodies erenumab/fremanezumab/galcanezumab/eptinezumab), and vestibular rehabilitation. Trigger identification and lifestyle modification.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Trigger of acute vestibular migraine attack from procedure stress or pain
  • Worsening of dizziness or imbalance after the procedure
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Fall risk during or after vertigo attack
  • Delay of CGRP monoclonal antibody or other preventive therapy
  • Risk of missed structural cause of vertigo (vestibular schwannoma)
Who should not consider this
  • Patients without a confirmed vestibular migraine diagnosis (Barany Society criteria)
  • Patients with suspected vestibular schwannoma or other structural cause (MRI required)
  • Patients with active acute migraine attack
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Pregnant patients
  • Patients who have not tried first-line preventive therapy (propranolol, topiramate, amitriptyline)
What to ask your clinician
  • Has my vestibular migraine diagnosis been confirmed using Barany Society criteria?
  • Have I had MRI to rule out vestibular schwannoma or central cause?
  • Have I tried first-line preventive medication (propranolol, topiramate, amitriptyline)?
  • Am I a candidate for CGRP monoclonal antibodies?
  • Have I had vestibular rehabilitation?
  • What evidence specifically supports leech therapy for vestibular migraine?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Sudden severe headache (worst of life — rule out subarachnoid hemorrhage)
  • New weakness, numbness, slurred speech, or vision loss (possible stroke)
  • Persistent vertigo with vomiting and inability to walk (possible cerebellar stroke)
  • New hearing loss with vertigo (possible labyrinthitis or vestibular schwannoma)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for vestibular migraine.
  • The absence of clinical studies in vestibular migraine, and small uncontrolled migraine reports, do NOT establish efficacy versus triptans, gepants, CGRP monoclonal antibodies, or preventive medication.
  • It does NOT replace MRI workup for structural causes when indicated.
  • It does NOT substitute for vestibular rehabilitation or evidence-based migraine prevention.
  • It does NOT distinguish vestibular migraine from stroke, Meniere disease, or vestibular schwannoma.

Clinical Profile

Category
Neurological
ICD-10
H81.8X9, G43.A0, G43.A1
Safety tier
Medium

Evidence Summary

Vestibular migraine is recognized by the Barany Society and IHS as a distinct migraine variant featuring vertigo episodes with migrainous features. Management is largely extrapolated from migraine care: lifestyle and trigger management, acute migraine therapy during attacks, prophylactic medication (propranolol, topiramate, amitriptyline, candesartan), and vestibular rehabilitation. The 2023 Cochrane reviews identified randomised evidence against placebo or no treatment only for metoprolol and flunarizine (prophylaxis) and for triptans (acute attacks), all of low or very low certainty, too uncertain to draw firm conclusions. No clinical study of leech therapy for vestibular migraine was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or Russian- and German-language sources (searched October 2026). The nearest data are two small migraine studies that were not specific to vestibular migraine (a 7-patient case series, Ansari 2019, and a 26-patient quasi-experimental pilot, Bakhshi 2015) and a Russian report of hirudotherapy in vascular cochleovestibular disorders (Morozova 2009). Any use is investigational and mechanistic only. Proposed mechanisms overlap with migraine prophylaxis discussions (modulation of cervico-cranial venous drainage and trigeminovascular inflammation) but remain speculative.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Vestibular schwannoma or other intracranial lesion not yet excluded
  • Untreated Meniere's disease (separate registry entry; different management)
  • Recent posterior circulation TIA or stroke
  • Discontinuation of migraine prophylaxis

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.